Zenbexus Combo Cuts Multiple Myeloma Progression Risk by 51% in Phase 3
BMY sits 40% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb reported positive topline results from the Phase 3 EXCALIBER-RRMM study: Zenbexus (iberdomide) plus daratumumab and dexamethasone (ZDd) achieved a median progression-free survival of 42 months versus 20 months for the standard-of-care DVd arm, a 51% reduction in risk of progression or death (HR 0.49, p<0.000001). This confirms the clinical benefit behind the FDA's August accelerated approval, which was based on MRD-negative complete response. The data will be presented at the ASH annual meeting. The magnitude of the PFS benefit is substantial and supports conversion to full approval and expanded use in earlier relapse settings.
At the time of this announcement, BMY was trading at $59.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $122B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.